• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Novel derivatives of guanine, viz. antiviral compounds of the formula …<CHEM>… wherein each of R1 and R2, which are the same or different is hydrogen, hydroxy or fluoro; provided that R1 or R2 is hydrogen when R1 and R2 are different, and provided that R1 and R2 are hydroxy or fluoro when R1 and R2 are the same; or a physiologically acceptable salt of an optical isomer thereof, methods for their preparation, pharmaceutical preparations containing the compounds, and methods for the treatment of virus infections and other diseases causes by viruses.
    公开号:SU1272992A3
    申请号:SU833657074
    申请日:1983-10-31
    公开日:1986-11-23
    发明作者:Эрик Хагберг Курт；Нильс-Гуннар Иохансон Карль；Мариа Илона Ковац Сусанна；Бертиль Штейнинг Геран
    申请人:Астра Лэкемедель Актиеболаг (Фирма)；
    IPC主号:
    专利说明:

     CM
    This invention relates to a process for the preparation of 9- (3,4-dioxybutyl) guanine, a new biologically active compound that can be used in medicine.
    The purpose of the invention is to create a method for obtaining a new guanine derivative having a higher antiviral activity.
    Example. To a suspension of 1 g of 4- (2-amino1, 6-dihydro-6-oxopurin-9-yl) -2-hydroxybutyric ethyl ester in 100 ml of isopropanol is added 1 g of sodium borane, and the mixture is heated with a reverse fridge for 8 h. Add hydrochloric acid to obtain a clear; g: solution (leutral pH). After removing the solution; 1), the residue is dissolved in a small; p; m of boiling water and under; 1 () W11Buyut for 6 hours. The solid is filtered, the filtrate is heated and under reduced pressure, the residue is dissolved in 1 mol / l hydrochloric acid and absorbed on the cation exchanger in the hydrogen form. ). The cation exchanger is treated with MFjnaioj with water and then eluted with 5% BUT ammonium hydroxide. The eluent upjekHKHOT and crystalline substance are recrystallized from water. A colorless product is obtained in the needle-shaped one (t.pl. 260-261 C (decomposition). Yield 0.4 g.
    UV spectrum (0.01 mol / l of hydrochloric acid; ornate acid) Ti "ks nm: 2.7, 253 (11500).
    Mass spectrum: 11.2 a3 (int.):;:; G :) (H 0.13); 222 (0.19); 221 (0. 1 1); 152 (0.43); 151 (0.56); A | (1.0).
    Biological tests of 9- (3, A - dioxybutyl) -guanine were carried out.
    Experiment 1. In order to demonstrate antiviral activity in the presence of vesicle deprivation of infections, guanine derivatives should be preliminarily translated into the corresponding monophosphates under the action of thymidine kinase of bubbly lichen.
    The sensitivity of guanine derivatives to the action of type I thymidine kinase from Vero cells from Vero cells, as well as the relative phosphorylation rate, are determined in accordance with the method of A. Larsson.
    In this case, the sensitivity is all the higher, the lower the K value;
    The results of the experiment are given in table.1.
    Table 1
    0.4 (km)
    100
    75
    1.5 173
    27
    The data table. 1 suggests that a new guanine derivative exhibits a better sensitivity to the action of thymidine kinase (and thus a better antiviral activity) than the known compound.
    In addition, when using a novel compound, a higher relative phosphorylation rate is observed.
    EXAMPLE 2. The degree of competition between thymidine and compounds with antiviral activity is determined in cells infected with bubble gland, according to the method of A. Larsson, which determines the concentration of the guanine derivative, providing 50% inhibition of spot lick formation, depending on the concentration of added thymidine (concentration of KTuo).
    The results of the experiment are given in table. 2
    100 micm thymidine
    5 Value -g.
     mikm thymidine
    for the proposed compound 6.1, and for the known compound - 28.
    Table 2.
    The method of obtaining 9 (3,4-dioxybutyl) -guanine of the formula
    Dany table. 2 shows that as the amount of thymidine added increases, the antiviral activity of a known compound decreases more than the antiviral activity of the proposed compound. When administered orally to dogs at doses of 45 and 140 mg / kg, the proposed compound does not cause any negative effects, and the known compound at a dose of 45 mg / kg causes diarrhea.
    NG1P
    -HzN- i- -C zCHsCH- CH20H
    HE
    characterized in that 4- (2-amino-1,6-dihydro-6-oxopurin-9-yl) -2-hydroxybutythyl ethyl ester
    acid formula

    Н21Д -СНгСН2СН-СООС Н5
    he
    sodium borane is reduced in isopropanol by boiling.
    权利要求:
    Claims (1)
    [1]
    Claim
    The method of obtaining 9 (3,4-dioxibutyl) -guanine of the formula
    3.9
    4.4
    100
    11.0 14.0
    X n
    Hffvv
    -HjN-Sj N_ sn hs g sn-sn 2 he he
    Danyye tab. 2 indicate that as the amount of thymidine added increases, the antiviral activity of the known compound decreases more than the antiviral 20 activity of the proposed compound. When administered orally to dogs at doses of 45 and 140 mg / kg, the proposed compound does not cause any adverse effects, and the known 25 compound at a dose of 45 mg / kg causes diarrhea.
    characterized in that 4- (2-amino-1,6-dihydro-6-oxopurin-9-yl) -2-hydroxybutyric acid ethyl ester of the formula
    HfcNjf — ТК-СЩСНзСН- СООС2Н5
    OH is reduced with sodium borane in isopropanol by boiling.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1272992A3|1986-11-23|Method of producing 9-|-guanine
    SU1225481A3|1986-04-15|Method of producing mixture of glyceryl-1,2 and 1,3-bis-| showing properties of central nervous system depressant
    DE2607620C2|1984-09-13|4-Amino-5-hexenoic acid and process for its preparation
    EP0011609B2|1988-05-11|Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
    CZ283721B6|1998-06-17|2-amino-9-/4-acetoxy-3-acetoxymethylbut-1-yl/purine its use for preparing pharmaceutical preparations and the pharmaceutical preparations containing thereof
    RO111847B1|1997-02-28|Optical izomer for the //4-|-phenyl/hydr azono/propane dinitrile, preparation process thereof and intermediaries for the process making thereof
    CH641471A5|1984-02-29|METHOD FOR PRODUCING PHYSIOLOGICALLY COMPATIBLE SALTS OF PHOSPHONIC ACID.
    CZ286621B6|2000-05-17|Tromethamine salt of |-|-2-|propionic acid, process of its preparation and pharmaceutical preparation containing thereof
    RU2157685C2|2000-10-20|Pharmaceutical composition showing antidepressant activity
    IE58393B1|1993-09-08|-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
    SK302003A3|2003-07-01|Stable gabapentin having pH within a controlled range
    US4472387A|1984-09-18|Pharmaceutical compositions capable of increasing cerebral serotonin concentration
    EP0132811A1|1985-02-13|1-Substituted 4-hydroxymethyl-pyrrolidinones, processes for their preparation, pharmaceutical composition and intermediate
    ES8308833A1|1983-10-01|Novel 3-phenyl-1-indanamines, pharmaceutical compositions and methods of preparation.
    SU1222197A3|1986-03-30|Method of producing bicyclic compounds or stereoisomers of the compounds or their pharmaceutically acceptable salts with acids
    US5789407A|1998-08-04|Method of treating depression with certain triazine derivatives
    US3362879A|1968-01-09|Tyrosine tranquilizing compositions and methods of treatment
    US4338319A|1982-07-06|Method for the treatment of chronic obstructive airway or cardiac diseases
    SE8601799D0|1986-04-18| - 1BETA-ETHYL-1ALFA-HYDROXYMETHYL-1,2,3,4,6,7,12,12BALFA-OCTAHYDROINDOLO / 2,3-A / QUINOLIZINE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
    US3751408A|1973-08-07|Imidazole-ribosyl cyclophosphate compounds and therapeutic compositions
    ES8106517A1|1981-08-01|10-halo-E-homoeburnane derivatives, a process for the preparation thereof, a process for the use thereof as vasodilators, and vasodilating compositions thereof
    US3917833A|1975-11-04|Amino-substituted benzocycloheptenones for inducing sleep
    FR2470110A1|1981-05-29|DECRAPENYLAMINE DERIVATIVES, THEIR ACID ADDITION SALTS AND PHARMACEUTICAL COMPOSITION COMPRISING THESE PRODUCTS
    CS221846B2|1983-04-29|Method of making the ethanolamine derivatives
    US4314060A|1982-02-02|Oxaalkanoate anti-ulcer compounds
    同族专利:
    公开号 | 公开日
    AU7872181A|1982-07-01|
    AT20748T|1986-08-15|
    NO822712L|1982-08-09|
    DK148279B|1985-05-28|
    FI822891L|1982-08-19|
    IL64501D0|1982-03-31|
    AU542373B2|1985-02-21|
    ZA818781B|1982-11-24|
    DK369982A|1982-08-18|
    WO1982002202A1|1982-07-08|
    EP0055239B1|1986-07-16|
    FI68054C|1985-07-10|
    DK148279C|1986-02-17|
    RO85288A|1984-11-25|
    IL64501A|1985-07-31|
    DE3174948D1|1986-08-21|
    FI68054B|1985-03-29|
    US4495190A|1985-01-22|
    CA1172633A|1984-08-14|
    EP0055239A1|1982-06-30|
    FI822891A0|1982-08-19|
    GR76971B|1984-09-04|
    SU1272991A3|1986-11-23|
    RO85288B|1984-11-30|
    JPS57501963A|1982-11-04|
    NZ199334A|1985-09-13|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    IL34188A|1969-04-09|1972-12-29|Seiyaku T Co|4--2,3-dihydroxy butyric acid and the preparation thereof|
    US3836656A|1972-02-07|1974-09-17|Sandoz Ag|Substituted purines as hypolipidemics|
    US4199574A|1974-09-02|1980-04-22|Burroughs Wellcome Co.|Methods and compositions for treating viral infections and guanine acyclic nucleosides|
    CS199093B1|1977-10-20|1980-07-31|Antonin Holy|Antiviral agent|
    US4230708A|1977-10-20|1980-10-28|Stichting Rega V.Z.W.|Therapeutic application of -or -9- adenine for use as antiviral agents|
    US4221910A|1978-09-15|1980-09-09|Newport Pharmaceuticals International, Inc.|9-purines|
    US4423050A|1981-05-21|1983-12-27|Syntex Inc.|9-guanine as antiviral agent|
    US4451478A|1982-03-12|1984-05-29|Newport Pharmaceuticals International, Inc.|Imidazole compounds|SE8203855D0|1982-06-21|1982-06-21|Astra Laekemedel Ab|NOVEL DERIVATIVES OF GUANINE I|
    SE8203856D0|1982-06-21|1982-06-21|Astra Laekemedel Ab|NOVEL DERIVATIVES OF GUANINE II|
    HUT36464A|1983-05-24|1985-09-30|Newport Pharmaceuticals|Process for producing erythro-4-amino-3-/2-hydroxy-3-alkyl/-imidazol-5-carboxamide|
    US5047533A|1983-05-24|1991-09-10|Sri International|Acyclic purine phosphonate nucleotide analogs|
    GB8320308D0|1983-07-28|1983-09-01|Wellcome Found|Antiviral combinations|
    EP0141927B1|1983-08-18|1991-10-30|Beecham Group Plc|Antiviral guanine derivatives|
    US5684153A|1984-08-16|1997-11-04|Beecham Group Plc|Process for the preparation of purine derivatives|
    IL73682A|1983-12-20|1991-08-16|Medivir Ab|Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation|
    US4579849A|1984-04-06|1986-04-01|Merck & Co., Inc.|N-alkylguanine acyclonucleosides as antiviral agents|
    US4801710A|1984-10-26|1989-01-31|Merck & Co., Inc.|Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives|
    YU45690B|1984-12-22|1992-07-20|Krka Tovarna Zdraviln.Sol.O.|PROCEDURE FOR PREPARING 9--GUANINE|
    EP0193454A1|1985-02-25|1986-09-03|Merck & Co. Inc.|8-Substituted-9-hydroxyalkyl and hydroxyalkoxymethyl-guanines and pharmaceutical compositions containing them|
    EP0219838A3|1985-10-22|1988-04-06|Takeda Chemical Industries, Ltd.|Carbocyclic purine nucleosides, their production and use|
    US5578468A|1987-08-10|1996-11-26|Duke University|Site-specific RNA cleavage|
    US5443964A|1987-08-10|1995-08-22|Duke University|Poxvirus insertion/expression vector|
    US4935427A|1987-12-31|1990-06-19|The United States Of America As Represented By The Department Of Health And Human Services|Pyrimidine and purine 1,2-butadiene-4-ols as anti-retroviral agents|
    US4966895A|1989-02-02|1990-10-30|Merck & Co. Inc.|Cyclic monophosphates of purine and pyrimidine acyclonucleosides as anti-retroviral agents|
    US5352669A|1990-03-13|1994-10-04|The Of The United States Of America As Represented By The Department Of Health And Human Services|O6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O6 -alkylguanine-DNA alkyltransferase depleting activity|
    US5091432A|1990-03-28|1992-02-25|Glasky Alvin J|9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use|
    SK280313B6|1990-04-24|1999-11-08|Ústav organické chemie a biochemie AV ČR|N- derivatives of purine and pyrimidine heterocyclic bases, process for their preparation and their use|
    US5368853A|1990-05-11|1994-11-29|The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services|Leukoregulin anti-viral therapy|
    JP2939646B2|1990-07-17|1999-08-25|チッソ株式会社|4-Substituted-2-hydroxybutanoic acid esters and production method|
    US5874578A|1992-07-13|1999-02-23|Bristol-Myers Squibb|Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process|
    US5525606A|1994-08-01|1996-06-11|The United States Of America As Represented By The Department Of Health And Human Services|Substituted 06-benzylguanines and 6-benzyloxypyrimidines|
    US6359114B1|1995-06-07|2002-03-19|Aphton Corp.|System for method for the modification and purification of proteins|
    US6060458A|1998-02-13|2000-05-09|The United States Of America As Represented By The Department Of Health And Human Services|Oligodeoxyribonucleotides comprising O6 -benzylguanine and their use|
    US7241890B2|2001-10-30|2007-07-10|Conforma Therapeutics Corporation|Purine analogs having HSP90-inhibiting activity|
    US20070129334A1|2001-10-30|2007-06-07|Conforma Therapeutics Corporation|Orally Active Purine-Based Inhibitors of Heat Shock Protein 90|
    MXPA06002997A|2003-09-18|2007-02-08|Conforma Therapeutics Corp|Novel heterocyclic compounds as hsp90-inhibitors.|
    BRPI0609509A2|2005-03-30|2010-04-13|Conforma Therapeutics Corp|pharmaceutically acceptable compound or a polymorph, solvate, tautomer, enantiomer, prodrug or salt thereof, pharmaceutical composition, and, use of the pharmaceutically acceptable compound, polymorph, solvate, tautomer, enantiomer, prodrug or salt|
    AU2006259431B2|2005-06-14|2011-09-29|Brigham Young University|Methods for selective N-9 glycosylation of purines|
    WO2007035963A2|2005-09-23|2007-03-29|Conforma Therapeutics Corporation|Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors|
    CN108912055B|2018-08-20|2020-06-30|河南师范大学|Method for synthesizing antiviral drug cidofovir intermediate and bucyclovir intermediate|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    SE8009040|1980-12-22|
    [返回顶部]